Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.
about
Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategiesReporter-Expressing, Replicating-Competent Recombinant ArenavirusesVaccines against tuberculosis: where are we and where do we need to go?KAP1 regulates gene networks controlling T-cell development and responsiveness.Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of miceEnhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles.The next 10 years for tuberculosis vaccines: do we have the right plans in place?Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsEvolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness.Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus.New approaches to design HIV-1 T-cell vaccinesBoth systemic and mucosal LCMV immunization generate robust viral-specific IgG in mucosal secretions, but elicit poor LCMV-specific IgA.Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression.Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trialsPseudotyping lentiviral vectors with lymphocytic choriomeningitis virus glycoproteins for transduction of dendritic cells and in vivo immunization.Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses.CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells.The Nucleoprotein Is Required for Lymphocytic Choriomeningitis Virus-Based Vaccine Vector Immunogenicity.Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.Efficiency of ferritin as an MRI reporter gene in NPC cells is enhanced by iron supplementationELL targets c-Myc for proteasomal degradation and suppresses tumour growth.Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells.Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primatesSuperoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative DamageRole of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future.Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8(+) T-cell priming and viral controlA Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose.Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancerHigh antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survivalpMHC affinity controls duration of CD8+ T cell-DC interactions and imprints timing of effector differentiation versus expansion.Reverse Genetics Approaches to Control Arenavirus.Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.Cytomegalovirus Vaccines: Current Status and Future Prospects.Subcutaneous cholera toxin exposure induces potent CD103⁺ dermal dendritic cell activation and migration.Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.
P2860
Q24599295-8FAA3AAB-3EA0-46F7-9857-714B3E0AE8C1Q26742028-C3666062-6E26-47C9-B761-BDD54C7E0EFAQ26992233-5774B61F-2416-4840-B808-573F6D7A7BA4Q27319505-DB364435-4ACB-46A3-BE5D-8EC73443130DQ28727249-827DEEF2-3A7A-4C66-8615-C345F1A7D28CQ30877907-F6550783-3C75-40F3-A393-6852299E7C0EQ33659150-7706D1A4-4468-41FD-B2C0-A952A529FC3BQ33762986-D22CC96C-D050-4432-8BCD-65754779755FQ33936327-564F81BC-7DB0-4CD0-8360-37106BC05DE5Q34057974-CA7CD8B2-C317-4481-9BE2-13081341E15DQ34128906-8802B272-20F5-47A6-8BE0-DB213CB4D5FAQ34261441-B677CEFF-0A66-4021-BD65-6548E55B95CAQ34274849-BBC53BA4-0432-4180-B0E5-7908872B807EQ34296797-7B0C282B-DEA7-4D08-87C3-A10169A627C2Q34411316-F5F9B517-6C62-49E9-A020-CC59521EE69AQ34671806-995809EB-B9CD-47A3-AFF8-C2D5DA033816Q34719449-D539E066-79DE-41E3-A52E-21691DEC2ECBQ34802680-761FE9EF-7533-4EE8-AF49-277C4DB931AFQ35567056-491BE108-083F-4FA2-B35E-3B71DDE58A98Q35768790-5E5F94A5-51CA-48CC-8D54-E2A736FB1F99Q35847032-92D4C26B-69E9-459A-96EF-7F299B540A02Q35878493-68737300-16C2-4064-84ED-E2A8116B049AQ35968349-676089E0-5A5F-467F-9761-9D464F2C3108Q36119591-DDB2AACE-90A7-4C89-A828-397B3C54B741Q36171855-3505E0D1-DCB8-490A-9004-ED43C5759A88Q36315988-D81C34E3-0707-430C-A75C-3F61EDEEE7B3Q36432691-CA4211C4-6FB9-48F6-AF38-96F36953DB31Q36501145-8FB1C2B2-E68C-49E3-AEB5-780A1421FD86Q36736786-073595F8-0734-404E-B5DB-04A81BDA0FF5Q36857863-289FF171-C7E8-42B3-92FF-0CF928A933D9Q37197889-21B5A8F1-ABEF-4682-A06F-D575F0842732Q37415209-73353DEE-43F8-4FE0-BC97-A129CA6B7AD7Q37543755-FE161B28-CC2C-4DC8-91E0-91B9BCDE4C3FQ37563632-E10C73FF-D0F8-4795-B217-480279B47F56Q37681801-C4EA9EB0-60FA-4F0F-8BE2-F875FA003135Q37714030-9EBC673F-B1C1-4BC0-90E0-A0CA0A89472FQ38789279-24B02C6D-7B51-488C-A377-C164400365A2Q38791353-820F915D-6EEF-4555-B3FF-0051205D0655Q38877891-4DE96A2F-1AB9-486D-97BB-33E4094CBE5CQ39549328-78BEE37A-D4FF-4552-A95D-45BFACC6A53A
P2860
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Development of replication-def ...... f potent CD8+ T cell immunity.
@ast
Development of replication-def ...... f potent CD8+ T cell immunity.
@en
type
label
Development of replication-def ...... f potent CD8+ T cell immunity.
@ast
Development of replication-def ...... f potent CD8+ T cell immunity.
@en
prefLabel
Development of replication-def ...... f potent CD8+ T cell immunity.
@ast
Development of replication-def ...... f potent CD8+ T cell immunity.
@en
P2093
P2860
P50
P356
P1433
P1476
Development of replication-def ...... of potent CD8+ T cell immunity
@en
P2093
Admar Verschoor
Adrian F Ochsenbein
Ahmed N Hegazy
Andreas Radbruch
Daniel D Pinschewer
Florian Kreppel
Frédéric Lévy
Luca Gattinoni
Lukas Flatz
Maries van den Broek
P2860
P2888
P304
P356
10.1038/NM.2104
P407
P577
2010-02-07T00:00:00Z